Bioada

Looking forward to hearing from our Chief Medical Officer, Mark Hiatt, this Tuesday at the Diagnostic Coverage & Reimbursement Conference in Boston, hosted by Q1 Productions. Dr. Hiatt, presenting alongside Point32Health, will discuss how diagnostic labs and health plans can improve access by aligning on evidence, community needs, and responsible innovation. At Bioada, we believe next-generation access strategy depends on pairing strong clinical validation with AI-powered insights that make diagnostics more predictive, reproducible, and widely adoptable. #Q1Productions #Reimbursement #AccessToCare #AIinHealthcare #diagnostics

We’re proud to share that our Chief Medical Officer, Dr. Mark Hiatt, has been invited to speak at Q1 Productions' upcoming Diagnostic Coverage & Reimbursement Conference in Boston this December. Dr. Hiatt will present on “Reducing Health Disparity and Increasing Access: What It Means for Diagnostic Labs and Health Plans,” highlighting the vital connection between equitable healthcare access and innovation in diagnostics. #AI #DrugDiscovery #PrecisionMedicine #Diagnostics #HealthcareInnovation

Excited to be in New York City for the #AVBCC Educational Summit, where our Chief Medical & Commercial Officer, Dr. Mark Hiatt, is contributing to the dialogue on advancing value in cancer care. Today he is: 🎤 Moderating “Right Test, Right Time: Driving Value in Precision Oncology” 🎤 Presenting “Is Value-Based Payment Compatible with Radiology and Pathology?” Grateful to join fellow leaders across payers, providers, pharma, and policy in shaping the future of cancer care. #AVBCC #PrecisionOncology #ValueBasedCare #CancerCare

We’re proud to share that our Chief Medical & Commercial Officer, Dr. Mark Hiatt, is speaking this week in New York City at the Association for Value-Based Cancer Care (AVBCC) Educational Summit & Program, a premier gathering of C-suite leaders shaping the future of cancer care. Dr. Hiatt will: - Moderate “Right Test, Right Time: Driving Value in Precision Oncology” - Present “Is Value-Based Payment Compatible with Radiology and Pathology?” AVBCC convenes over 300 nationally recognized experts across 90+ sessions, offering unmatched collaboration and exchange among payers, providers, pharma, specialty pharmacy, and policy leaders. This invitation-only event fosters the real-world insights needed to close cost and quality gaps and advance patient-centered cancer care. We’re honored to contribute Bioada’s perspective to this unique ecosystem. #AVBCC #PrecisionOncology #ValueBasedCare #CancerCare #Diagnostics #HealthPolicy

ADCs represent one of oncology’s most promising therapeutic classes, yet their development remains constrained by legacy frameworks and trial-and-error design. In this new piece, we explore the critical question: How can data-driven discovery unlock the next generation of ADCs, ones that truly match molecular precision with clinical efficacy? The article examines: - The systemic challenges limiting ADC innovation - Lessons from market successes and withdrawals - How new AI-powered, multi-omics frameworks can redefine how we design and test ADCs We invite the ADC community to join the conversation, especially the pioneers shaping this field: Seagen (now part of Pfizer), AstraZeneca, Daiichi Sankyo, Gilead Sciences, AbbVie, ImmunoGen, Inc. Roche, ADC Therapeutics, Astellas Pharma, GSK. https://lnkd.in/eDNkDzuE — At Bioada, we believe innovation in oncology should no longer depend on chance. Our AI-powered Genomarker platform helps reveal the true molecular drivers of therapeutic response, transforming ADC development from empirical to evidence-anchored. #AntibodyDrugConjugate #ADC #Oncology #Biotech #Pharma #PrecisionMedicine #TranslationalScience #DrugDevelopment #Innovation #Genomarker #AIinBiotech #DataDrivenDiscovery #MolecularTherapeutics #PharmaR&D

We’re honored that Bioada was recognized by MaRS Discovery District as one of the ventures driving innovation in #Parkinson’s care. At Bioada, our mission is to bring precision medicine to patients by solving the biomarker reproducibility crisis and unlocking new therapeutic avenues. In Parkinson’s disease, this has already led to: - A liquid biopsy biomarker for early detection using a single gene in the blood, with both sensitivity and specificity above 95%. - The discovery of a novel driver gene, opening the door to targeted therapies that could transform patient outcomes. MaRS Connect is helping ventures like ours scale faster by bridging the gap between science, patients, investors, and healthcare leaders. We look forward to continuing this journey and to making a lasting impact for people living with Parkinson’s.

A message to pharma and academia: it’s time to rethink what you've long accepted. https://lnkd.in/e4gbZ7ub #ParkinsonsDisease #DrugDiscovery #Biotech #Neuroscience #Bioada #Diagnostics #AlphaSynuclein #Biogen #Roche #Prothena #Takeda #AbbVie #AstraZeneca #NCERPD #PPMI #TranslationalMedicine #PrecisionMedicine

We’re excited to officially welcome Dr. Roy Shapiro as Strategic Advisor at Bioada. Dr. Shapiro brings over 30 years of experience at the intersection of medicine, finance, and innovation. A board-certified radiologist, he transitioned from clinical practice to become a trusted advisor to venture firms, institutional investors, and private equity groups across the U.S., Europe, and the Middle East. Throughout his career, he has played a pivotal role in raising significant capital, scaling companies in the life sciences and healthcare sectors, and successfully guiding four companies to IPO. His unique combination of clinical insight and strategic capital expertise makes him an invaluable addition to Bioada at this transformative stage. In his role, Dr. Shapiro will work closely with our executive leadership team to advance global validation initiatives, strengthen investor engagement, and support strategic expansion across all business verticals. Please join us in welcoming Dr. Shapiro to the Bioada leadership team. We’re proud to have him on board as we continue shaping the future of precision medicine.

We’re proud to share that our Chief Medical and Commercial Officer, Dr. Mark Hiatt, has been invited to co-present at the upcoming Next Generation Dx Summit in Washington, DC, hosted by Cambridge Healthtech Institute. Mark will be joined by Dhruvajyoti Roy, Ph.D. of MD Anderson to present: “Emerging Trends in Biomarker-Driven Therapies: The Future of Precision Oncology Guided by Companion Diagnostics” This session will explore how AI, next-generation sequencing (NGS), and real-world data (RWD) are enabling a new era in personalized medicine. #Bioada #NGDx #CompanionDiagnostics #PrecisionMedicine #LiquidBiopsy #RWD #NGS #AIinHealthcare #Oncology #BiotechLeadership #HealthTech #DiagnosticsInnovation

🔊 Mark Hiatt to Moderate at Medical Device Coverage & Reimbursement Conference We’re proud to share that Dr. Mark Hiatt, Chief Medical and Commercial Officer at Bioada, will be moderating two sessions this week at the Q1 Productions’ Medical Device Coverage & Reimbursement Conference in Nashville. This premier event brings together key stakeholders—payers and innovative medtech companies—to tackle evolving medical policy, reimbursement pathways for medical devices, and strategies to strengthen petitions for coverage and appeals. 🗣️ Dr. Hiatt will be leading conversations on: ✅ Approaches to Gain Coverage with Employer Groups (with Tim Johnstad, HealthCheck360) • Navigating employer-sponsored health plan decisions • Engaging benefits managers, HR leaders & TPAs • Aligning data with employer priorities for health & cost savings • Building long-term value and renewal strategies ✅ Independent Review: Impact on Coverage & Reimbursement of Medical Devices (with Edward Bolton, CEO of Nexus) • How IROs interact with health plans • Strengthening clinical & economic evidence for coverage • Avoiding common pitfalls in evidence submission • Clarifying discrepancies & reinforcing key evidence We’re excited to see Dr. Hiatt bring his perspective to this dynamic forum and contribute to shaping the future of medical device access. #Bioada #MarketAccess #MedicalDevices #Reimbursement #HealthTech #EmployerCoverage #IROs #PrecisionMedicine #Q1Productions #MedTech